In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 121 to 130 of 404

TitleTypeExpected publication date
Elacestrant for treating oestrogen receptor-positive, HER2-negative advanced breast cancer with an ESR1 mutation after at least 1 endocrine treatment [ID6225]Technology appraisal guidanceTBC
Electrically stimulated intravesical therapy for interstitial cystitis or overactive bladder in adultsInterventional procedures guidance
Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments [ID4026]Technology appraisal guidance
Empagliflozin for preventing cardiovascular events after acute myocardial infarction [ID6240]Technology appraisal guidanceTBC
Encorafenib with binimetinib for treating BRAF V600E mutation-positive advanced non-small-cell lung cancer [ID6177]Technology appraisal guidance
Endoscopic bipolar radiofrequency ablation for treating biliary obstruction caused by cholangiocarcinoma or pancreatic adenocarcinomaInterventional procedures guidanceTBC
Enfortumab vedotin for treating locally advanced or metastatic urothelial cancer after 2 therapies [ID3845]Technology appraisal guidance
Enfortumab vedotin with pembrolizumab for first-line treatment of unresectable or metastatic urothelial cancer who are eligible for platinum-containing chemotherapy [ID6332]Technology appraisal guidance
Epcoritamab for treating relapsed or refractory follicular lymphoma ID6338Technology appraisal guidanceTBC
Epilepsies in children, young people and adults (extraordinary review)NICE guidelineTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All